Tests reduced chemotherapy with an antibody treatment for children with neuroblastoma
Tests whether reduced chemotherapy plus an antibody is safe in children with high-risk neuroblastoma.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 45 people, planned
- Started
- 22 Jul 2024
- Expected to end
- 22 Jul 2029
- Type of study
- Interventional
- Treatments tested
- DANYELZA
- Sargramostim
- Cytoxan
- Topotecan
- Vincristine
- Doxorubicin
- Ifosfamide
- Etoposide
- Carboplatin
- Irinotecan
- Temozolomide
- Radiation Therapy
- Record updated
- 28 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with high-risk neuroblastoma who have had little or no chemotherapy so far.
- Age
- From 18 Months to 19 Years. The inclusion list says under 19 years.
- Sex
- All sexes can join.
- Disease stage
- High-risk neuroblastoma: MYCN-amplified stage L2/M/MS at any age, or stage M in children older than 18 months. Neuroblastoma must be confirmed by tissue exam, bone marrow spread plus high urine catecholamine levels, or a positive MIBG scan.
- Earlier treatment
- No more than one earlier cycle of high-risk neuroblastoma chemotherapy.
- Biomarker or test result
- MYCN amplification is required for stage L2/M/MS. It is not required for stage M in children older than 18 months.
Main reasons for not taking part
- Severe problems with major organs (kidney, heart, liver, nerves, lungs, blood, gut), grade 3 or worse
- Organ problems caused directly by the tumour or its spread do not count as a reason to exclude
- Cannot follow the trial requirements
- Pregnancy
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan
- HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients >18 months old
- No more than one prior cycle of HR-NB chemotherapy
- Age <19 years
- Signed informed consent indicating awareness of the investigational nature of this treatment
Who cannot take part
- Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >/= to grade 3; °Organ dysfunction due to direct effects of primary tumor or metastatic disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., steroid- induced hyperglycemia or hypertension) will also not be considered in exclusion criteria
- Inability to comply with protocol requirements
- Pregnancy
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Brian Kushner, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
The group in the trial
- Participants with NeuroblastomaTreatment being tested
Participants will receive 4 cycles of induction chemotherapy followed by a response-based intervention.
Treatment: DANYELZA, Sargramostim, Cytoxan, Topotecan, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Carboplatin, Irinotecan, Temozolomide, and Radiation Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- N10: Reduced Therapy for High-Risk Neuroblastoma
- Plain-language title
- Tests reduced chemotherapy with an antibody treatment for children with neuroblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 August 2026